Roche says new haemophilia drug cuts bleed rate by 87 pct

Roche says new haemophilia drug cuts bleed rate by 87 pct


Roche's investigational hemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year hemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire.



from Biotech News